{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:08:42Z","timestamp":1791065322863,"version":"4.1.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"Importance<\/jats:title>Hidradenitis suppurativa is a painful immune-mediated disorder with limited treatment options; hence, a need exists for new treatments.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the feasibility of heat shock protein 90 inhibition by RGRN-305 as a novel mechanism of action in treating moderate to severe hidradenitis suppurativa.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This was a parallel-design, double-blind, proof-of-concept, placebo-controlled randomized clinical trial conducted between September 22, 2021, and August 29, 2022, at the Department of Dermatology, Aarhus University Hospital in Denmark. The study included a 1- to 30-day screening period, a 16-week treatment period, and a 4-week follow-up period. Eligibility criteria included age 18 years or older and moderate to severe hidradenitis suppurativa with 6 or more inflammatory nodules or abscesses in at least 2 distinct anatomic regions. Of 19 patients screened, 15 patients were enrolled in the study. Intention-to-treat analysis was performed.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Patients were randomly assigned (2:1) to receive oral RGRN-305, 250-mg tablet, or matching placebo once daily for 16 weeks.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary efficacy end point was the percentage of patients achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR-50) at week 16. Secondary efficacy end points included HiSCR-75 or HiSCR-90, Hidradenitis Suppurativa Physician\u2019s Global Assessment, Dermatology Life Quality Index scores, and a pain numeric rating scale. Safety was assessed by adverse events, physical examinations, clinical laboratory measurements, and electrocardiograms.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 15 patients were enrolled, completed the study, and were included in all analyses (10 [67%] female; median age, 29 [IQR, 23-41] years). The primary end point HiSCR-50 at week 16 was achieved by a higher percentage in the RGRN-305 group (60% [6 of 10]) than in the placebo group (20% [1 of 5]). Improvements were also observed across all secondary end points at week 16, including higher rates of the harder-to-reach HiSCR levels; 50% (5 of 10) achieved HiSCR-75 and 30% (3 of 10) achieved HiSCR-90, whereas none of the placebo-treated patients achieved HiSCR-75 or HiSCR-90. RGRN-305 was well tolerated, with no deaths or serious adverse events, and treatment-emergent adverse events were similarly frequent between the RGRN-305 and placebo groups.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The findings of this trial suggest that heat shock protein 90 inhibition by RGRN-305 offers a novel mechanism of action in treating hidradenitis suppurativa, warranting further evaluation in larger trials.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT05286567<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.4800","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T16:03:05Z","timestamp":1701878585000},"page":"63","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa"],"prefix":"10.1001","volume":"160","author":[{"given":"Hakim","family":"Ben Abdallah","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bregnh\u00f8j","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Emmanuel","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Ghatnekar","sequence":"additional","affiliation":[{"name":"Regranion, Mount Pleasant, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Johansen","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Iversen","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"doi230058r1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/jdv.v35.1","article-title":"Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life.","volume":"35","author":"Nguyen","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"doi230058r2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMcp1014163","article-title":"Clinical practice: hidradenitis suppurativa.","volume":"366","author":"Jemec","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"doi230058r3","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/bjd.v183.6","article-title":"Aetiology and pathogenesis of hidradenitis suppurativa.","volume":"183","author":"Wolk","year":"2020","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi230058r4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa.","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"doi230058r5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/PTT.S294173","article-title":"Key signaling pathways in psoriasis: recent insights from antipsoriatic therapeutics.","volume":"11","author":"Ben Abdallah","year":"2021","journal-title":"Psoriasis (Auckl)"},{"issue":"5","key":"doi230058r6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa.","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"doi230058r7","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial.","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"13","key":"doi230058r8","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s40265-022-01764-6","article-title":"Pimitespib: first approval.","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"issue":"11","key":"doi230058r9","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41580-023-00640-9","article-title":"Structural and functional complexity of HSP90 in cellular homeostasis and disease.","volume":"24","author":"Chiosis","year":"2023","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"doi230058r10","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.annonc.2022.05.518","article-title":"Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial.","volume":"33","author":"Kurokawa","year":"2022","journal-title":"Ann Oncol"},{"issue":"5","key":"doi230058r12","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/bjd.v186.5","article-title":"HSP90 inhibitor RGRN-305 for oral treatment of plaque-type psoriasis: efficacy, safety and biomarker results in an open-label proof-of-concept study.","volume":"186","author":"Bregnh\u00f8j","year":"2022","journal-title":"Br J Dermatol"},{"key":"doi230058r13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1128897","article-title":"Heat shock protein 90 inhibitor RGRN-305 potently attenuates skin inflammation.","volume":"14","author":"Ben Abdallah","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"doi230058r15","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/jdv.2016.30.issue-6","article-title":"HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.","volume":"30","author":"Kimball","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"doi230058r16","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi230058r17","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1365-2133.2011.10698.x","article-title":"Adalimumab (antitumour necrosis factor-a) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study.","volume":"166","author":"van der Zee","year":"2012","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi230058r18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/bjd.2011.165.issue-2","article-title":"A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.","volume":"165","author":"Miller","year":"2011","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi230058r19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","article-title":"Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial.","volume":"80","author":"Vossen","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"10378","key":"doi230058r20","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"doi230058r21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: asx publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II, topical, intralesional, and systemic medical management.","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"doi230058r28","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1080\/14656566.2022.2070429","article-title":"Advances in biologic and small molecule therapies for hidradenitis suppurativa.","volume":"23","author":"Chen","year":"2022","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"doi230058r33","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/exd.v30.issue-6","article-title":"The HSP90 inhibitor RGRN-305 exhibits strong immunomodulatory effects in human keratinocytes.","volume":"30","author":"Hansen","year":"2021","journal-title":"Exp Dermatol"},{"issue":"12","key":"doi230058r34","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1002\/art.v58:12","article-title":"Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis.","volume":"58","author":"Rice","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"3","key":"doi230058r35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/cmi.2012.5","article-title":"Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL\/lpr mouse model of systemic lupus erythematosus.","volume":"9","author":"Shimp","year":"2012","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"doi230058r36","doi-asserted-by":"publisher","first-page":"563","DOI":"10.4049\/jimmunol.1000222","article-title":"EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity.","volume":"186","author":"Yun","year":"2011","journal-title":"J Immunol"},{"issue":"7","key":"doi230058r37","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1164\/rccm.200702-291OC","article-title":"Heat shock protein 90 inhibitors prolong survival, attenuate inflammation, and reduce lung injury in murine sepsis.","volume":"176","author":"Chatterjee","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"doi230058r38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/imm.v162.1","article-title":"Inhibition of the NLRP3 inflammasome by HSP90 inhibitors.","volume":"162","author":"Nizami","year":"2021","journal-title":"Immunology"},{"issue":"5","key":"doi230058r39","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/annonc\/mdv031","article-title":"Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase.","volume":"26","author":"Isambert","year":"2015","journal-title":"Ann Oncol"},{"key":"doi230058r11","author":"Li","year":"2021"},{"key":"doi230058r14","unstructured":"Sealed Envelope. Create a randomisation list: v1.23.0. Accessed June 2021. https:\/\/www.sealedenvelope.com\/simple-randomiser\/v1\/lists"},{"key":"doi230058r22","unstructured":"Novartis. Novartis receives European approval for Cosentyx as first and only IL-17A inhibitor for hidradenitis suppurativa. June 1, 2023. Accessed August 12, 2023, https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-european-approval-cosentyx-first-and-only-il-17a-inhibitor-hidradenitis-suppurativa"},{"key":"doi230058r23","unstructured":"UCB. Bimekizumab phase 3 data in hidradenitis suppurativa show clinically meaningful, deep and maintained response over 48 weeks. Accessed September 11, 2023. https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/Bimekizumab-Phase-3-Data-in-Hidradenitis-Suppurativa-Show-Clinically-Meaningful-Deep-and-Maintained-Response-over-48-Weeks"},{"key":"doi230058r24","unstructured":"AnaptysBio. AnaptysBio reports harp phase 2 top-line data of imsidolimab in moderate-to-severe hidradenitis suppurativa. August 31, 2022. Accessed February 12, 2023. https:\/\/ir.anaptysbio.com\/news-releases\/news-release-details\/anaptysbio-reports-harp-phase-2-top-line-data-imsidolimab"},{"key":"doi230058r25","unstructured":"A global study comparing risankizumab to placebo in adult participants with moderate to severe hidradenitis suppurativa (DETERMINED 1). Clinicaltrials.gov identifier: NCT03926169. August 11, 2022. Accessed October 18, 2023. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03926169"},{"key":"doi230058r26","unstructured":"A study to evaluate the efficacy, safety, and tolerability of guselkumab for the treatment of participants with moderate to severe hidradenitis suppurativa (HS) (NOVA). Clinicaltrials.gov identifier: NCT03628924. June 14, 2021. Accessed October 18, 2023. https:\/\/clinicaltrials.gov\/study\/NCT03628924"},{"key":"doi230058r27","unstructured":"A study to evaluate the efficacy and safety of imsidolimab (ANB019) in the treatment of subjects with hidradenitis suppurativa. Clinicaltrials.gov identifier: NCT04856930. February 15, 2023. Accessed October 18, 2023. https:\/\/clinicaltrials.gov\/study\/NCT04856930"},{"key":"doi230058r29","unstructured":"To assess the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa. Clinicaltrials.gov identifier: NCT04476043. September 28, 2023. Accessed October 18, 2023. https:\/\/clinicaltrials.gov\/study\/NCT04476043"},{"key":"doi230058r30","unstructured":"A study of oral upadacitinib tablet compared to placebo in adult participants with moderate to severe hidradenitis suppurativa to assess change in disease symptoms. February 6, 2023. Accessed October 18, 2023, Clinicaltrials.gov identifier: NCT04430855. https:\/\/clinicaltrials.gov\/study\/NCT04430855"},{"key":"doi230058r31","unstructured":"BioSpace. Aclaris Therapeutics announces preliminary topline data from 12-week phase 2a study of oral zunsemetinib (ATI-450) for moderate to severe hidradenitis suppurativa. Updated March 6, 2023. Accessed April 5, 2023. https:\/\/www.biospace.com\/article\/releases\/-aclaris-therapeutics-announces-preliminary-topline-data-from-12-week-phase-2a-study-of-oral-zunsemetinib-ati-450-for-moderate-to-severe-hidradenitis-suppurativa\/"},{"key":"doi230058r32","unstructured":"Pfizer. Safety and efficacy of PF-06650833, PF-06700841, and PF-06826647 in adults with moderate to severe hidradenitis suppurativa. 2023. Accessed April 5, 2023. https:\/\/www.pfizer.com\/science\/clinical-trials\/plain-language-study-results-summaries\/safety-and-efficacy-pf-06650833-pf"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2812209\/jamadermatology_ben_abdallah_2023_oi_230058_1705092725.93648.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T17:54:45Z","timestamp":1705514085000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2812209"}},"subtitle":["A Parallel-Design Double-Blind Trial"],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.4800","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,1]]}}}